ART Advanced Research Technologies Announces Q3 2007 Financial Results Conference Call
09 November 2007 - 8:44AM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, invites you to
participate in a conference call to discuss the company's financial
results for the third quarter ended September 30, 2007. The
conference call will follow the press release issued earlier on the
same day, and will be held on:
Wednesday, November 14, 2007
5:00 p.m. (EST)
To participate in the conference call when dialing within the
Montreal area, please dial (514) 861-1531, or (877) 667-7766 for
the rest of North America. Outside of North America, please dial
(514) 861-1531. Participants are asked to dial 10 minutes prior to
the start time.
The conference call will feature Sebastien Gignac, President and
Chief Executive Officer, and Jacques Bedard, Chief Financial
Officer.
If you are unable to participate, a replay of the conference
call will be available until November 22, 2007. To listen to the
replay from the Montreal area, please dial (514) 861-2272, or,
(800) 408-3053 for the rest of North America. From outside of North
America, please dial (514) 861-2272. The access code for the replay
is 3241023#.
We look forward to your participation and thank you for your
interest in ART Advanced Research Technologies Inc.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is distributed directly by ART in North America and Europe
and is used by industry and academic leaders worldwide. The
SoftScan� optical breast imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
the SoftScan optical medical imaging device via a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. Finally, the Fenestra� line of molecular imaging contrast
products provide image enhancement for a wide range of preclinical
Micro CT applications allowing scientists to see greater detail in
their imaging studies, with potential extension into other major
imaging modalities. The distribution of the Fenestra line of
imaging contrast agents is made through GE Healthcare Bio-Science
KK in Japan and is sold directly by the Company in the rest of the
world. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at
www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024